PDCD1 and neoplasm: This lays the foundation of checkpoint blockade of the PD-1–PD-L pathway to unleash the effector functions of T cells and reinvigorate the killing of tumor cells, and also highlights the value of PD-L1 expression as a predictive biomarker for this class of therapy.